InstrumentCube
Products

Home/News/Puji participated in the 818 Biomedical New Technology Conference to exchange testing applications in the field of CGT.
Company News

Puji participated in the 818 Biomedical New Technology Conference to exchange testing applications in the field of CGT.

Instrument.com.cn Sep 7, 2026

Puji participated in the 818 Biomedical New Technology Conference to exchange testing applications in the field of CGT.




Summary of the foreword of the meeting |QIAN YAN

August 18-19, 2026Biomedical New Technology Clinical Research and Translational Application Conference (818 Conference)Successfully held in Beijing. After the official implementation of Order No. 818 of the State Council,The first to focus on the entire industry chain of IIT (investigator-initiated clinical research)This conference brings together regulatory representatives from the National Health Commission and the Beijing Municipal Science and Technology Commission, 50+ top tertiary hospital managers such as Union Hospital and Peking University Third Hospital, as well as domestic and overseas CGT innovation companies such as Eso Biotec and Yimiao Shenzhou to discuss "how China's IIT efficiency advantages can help accelerate the implementation of global cell and gene therapy."

As a representative company in the field of scientific instruments, Puxi was invited to participate in the exhibition. This is also Puxi's first attempt to enter the biomedical new technology transformation track. Through the exhibition's deep link with the industry's core decision-makers, it has laid a good foundation for subsequent service compliance testing needs in the CGT field.


Part

01

picture

Anchoring new opportunities for the implementation of Order 818

A general analysis of the pain points of accurate docking industry

picture

The core background of this conference is to be officially implemented on May 1, 2026"Regulations on the Administration of Clinical Research and Clinical Transformation Application of New Biomedical Technologies" (State Council Order No. 818), the regulations clearly require that the entire IIT process must comply with quality control standards. Instrument stability and data traceability in cell preparation, testing and release have become core concerns for hospitals and enterprises.

picture

The Puxi booth focused on displaying star products suitable for CGT detection scenarios such as atomic absorption spectrophotometers, liquid chromatographs, and pure water equipment. In response to the requirements proposed by the conference“Hospitals lack quality control standards, supply chains lack access channels, and project parties lack compliance testing plans.”On the three major pain points, on-site technicians introduced in detail to the visiting guests the compliance solutions of Puranalyzer instruments in heavy metal detection, cell culture water quality control, and complete testing of finished products, especially the equipment data audit tracking, full-process traceability and other functions, which fully meet the requirements of Order No. 818 for clinical research record retention and quality traceability.

picture


Part

02

picture

Communicate in depth with core decision-makers

Lock in intention for subsequent cooperation

picture
picture

During the meeting, the Puji market team focused on connecting with the heads of scientific research departments, cell centers, and ethics committees of more than 20 tertiary hospitals participating in the meeting, as well as representatives of more than 10 CGT innovative companies and CDMO companies, and conducted one-on-one communication around actual testing needs:

·Commonly reported in tertiary hospitals“IIT project quality control system is weak and cell preparation and release standards are missing”Problem, general analysis team combinationHigh sensitivity and low detection limit of atomic absorption spectrometerAdvantages: It provides a full-process solution for the detection of heavy metals and harmful elements, and has been recognized by many hospital laboratory departments and GCP agencies;

· For CDMO companies“Compliance costs are high and testing efficiency needs to be improved”demand, PLC officially entered the core scene of CDMO: markingDomestic liquid phase has entered the stage of "innovative drug CMC registration level application" from "routine quality control"——Farewell to the traditional positioning of only serving finished product release, traditional Chinese medicine and environmental testing,PLC has been integrated into process development and clinical sample testing to meet registration-level data compliance requirements, substantially breaking the lock-in situation of imported equipment in head CDMOs and verifying the high-end reliability of domestic instruments under the GMP system;

· In response to the project party’s request that “the IIT phase testing budget is limited and the data needs to be quickly produced to support financing”, Puji put forwardA cost-effective modular testing configuration solution that balances compliance and cost pressures.

After two days of in-depth exchanges, the Puji market team has reached preliminary intentions with a number of key hospitals and innovative companies, and has agreed that after the meeting, they will carry out special demand surveys and output customized testing solutions.


Part

03

technology-based

Full category coverage of innovative therapy testing needs

This participation isPuji's debut in the field of new biomedical technologies is a landmark move for domestic scientific instruments to enter the high-end biopharmaceutical track.. Currently, innovative drugs and innovative therapies have entered a period of parallel explosion of multiple technical routes: from cell therapy, gene therapy, gene editing, to 14 subcategories such as autoimmunity, exosomes, small nucleic acids, In Vivo editing, IPSC, peptides, organoids and organoid chips, all of which have put forward rigid demands for laboratory infrastructure, core analytical instruments and compliance testing capabilities.

In view of the pain points in the research and development and transformation of the above-mentioned full categories of innovative therapies, Puji has formed a comprehensive coverage"Laboratory Infrastructure-Core Testing-Compliance Guarantee"Full chain support capacity:

· Basic support layer:The high-purity laboratory pure water system provides "water baseline" guarantee for various therapy research and development, meeting the ultrapure water requirements for cell culture, reagent preparation, and instrument sampling;

· Core detection layer:Atomic absorption spectrophotometer covers the detection of heavy metals and harmful elements to meet the safety evaluation requirements of cell products; liquid chromatographIt is suitable for scenarios such as small nucleic acid purity analysis, peptide content determination, exosome marker detection, organoid culture fluid component analysis, etc., to support process development and quality control release;

·Compliance assurance layer:The entire series of equipment is equipped with data audit tracking, electronic signature, and authority management functions, meeting the stringent requirements of Order 818 and GMP for data integrity and traceability, and providing a trusted data base for IIT filing, clinical transformation, and registration declaration.



Conclusion of the meeting |HUI YI JIE YU

In the next step, Puji will continue to delve into the field of biomedicine, closely follow the requirements of IIT regulatory policies, rely on the "government, industry, academia, research and medicine" collaborative innovation platform established at this conference, link up with core resources such as the Beijing Yizhuang Biomedicine Public Service Platform, and provide hospitals, CDMOs, and innovative pharmaceutical companies with customized services from equipment supply, method development to personnel training. We will use high-quality domestic instruments to help China's innovative therapies be transformed safely and efficiently, and provide solid "Chinese equipment" support for the development of new global biomedical technologies.

Beijing Purkinje General Instrument Co., Ltd.
Main products: Liquid Chromatograph (LC), UV-Vis Spectrophotometer, Atomic Fluorescence Spectrometer (AFS), Atomic Absorption Spectrometer (AAS)